Pharmacyclics' (NASDAQ: PCYC) share price has tripled in the last 12 months, and its shares saw another 7% jump today after the company's flagship drug, Ibrutinib, was given the Breakthrough Therapy Designation from the FDA. This is also positive news for the company's partner, Johnson & Johnson, which has already paid Pharmacyclics $300 million and could give another $675 million if Ibrutinib meets its remaining milestones. In this video, health care analyst Max Macaluso discusses today's news.
S&P 500
5,966.54
+0.5%
+$30.60
DJI
42,525.91
+0.5%
+$220.43
NASDAQ
19,381.40
+0.7%
+$138.79
Bitcoin
105,962.00
+1.5%
+1,597.00
AAPL
$202.75
+0.5%
+$1.05
AMZN
$206.01
-0.3%
-$0.64
GOOG
$169.01
-0.8%
-$1.36
META
$667.83
-0.5%
-$3.07
MSFT
$462.89
+0.2%
+$0.92
NVDA
$140.65
+2.4%
+$3.27
TSLA
$346.98
+1.3%
+$4.29
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Good news from the FDA for Pharmacyclics.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.